This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.
NextGen (NXGN) Reinforces Its Robust Solutions Portfolio
by Zacks Equity Research
NextGen's (NXGN) solid solutions portfolio receives further boost with the success of its Population Health tool.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Laboratory Corporation of America, Hologic, IDEXX Laboratories and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Laboratory Corporation of America, Hologic, IDEXX Laboratories and Thermo Fisher Scientific
Veeva (VEEV) Vault Applications Get Adopted by GenesisCare
by Zacks Equity Research
Veeva Systems' (VEEV) clinical capabilities will allow GenesisCare Clinical CRO to rationalize trial procedures and expedite execution of the same.
CVS Health (CVS) 2021 Selling Season Strong, LTC Arm Suffers
by Zacks Equity Research
Since the start of the pandemic, CVS Health (CVS) is seeing more than 40% of all specialty orders being placed digitally.
Boston Scientific's (BSX) SCS Systems Receives FDA's Nod
by Zacks Equity Research
Boston Scientific's (BSX) WaveWriter Alpha portfolio of SCS Systems aims to widen the therapy options available for managing chronic pain.
Baxter's (BAX) Vital Edge Program Aids Patient Blood Management
by Zacks Equity Research
Baxter's (BAX) Vital Edge program enables AdventHealth Tampa to achieve cost savings.
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.
3 Growth Stocks to Tap the COVID-Driven Shift in MedTech
by Urmimala Biswas
To beat the pandemic blues and maximize capital gains, investors can now scoop up these fundamentally-strong MedTech growth stocks.
Abbott's (ABT) Libre 2 Cleared in Canada, Boosts CGM Prospects
by Zacks Equity Research
Abbott's (ABT) next-generation FreeStyle Libre 2 system aims to provide a better quality of life to diabetics in Canada at the same affordable price of the current FreeStyle Libre system.
Cooper Companies (COO) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter earnings reflect weak segmental performance. However, it exceeds expectation as it witnesses faster-than-anticipated recovery.
Here's Why You Should Invest in Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and buyouts.
Why You Should Retain Pacific Biosciences (PACB) Stock Now
by Zacks Equity Research
Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of its solid prospects.
Zimmer Biomet (ZBH) Boosts Portfolio With A&E Medical Buyout
by Zacks Equity Research
This latest development aligns with Zimmer Biomet's (ZBH) active portfolio management strategy and the ongoing transformation of business aimed at long-term growth.
BD (BDX) to Boost Pre-Fillable Syringe-Manufacturing Capacity
by Zacks Equity Research
BD (BDX) is set to improve its pre-fillable syringe-manufacturing ability with its expansion and upgrade plans.
Hologic's (HOLX) New AI Technology Now Available Post FDA Nod
by Zacks Equity Research
Hologic's (HOLX) latest 3D CAD solution is expected to aid in early detection of breast cancer along with prioritizing the most concerning patient cases.
Veeva Systems (VEEV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) core Subscription Service and Professional Service segments deliver an impressive performance in Q3.
Patterson Companies (PDCO) Q2 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter 2021 results benefit from strong segmental performance.
AMN Healthcare (AMN) Boosts Service Portfolio With New Offering
by Zacks Equity Research
AMN Healthcare's (AMN) new pledge to provide support minority-owned businesses, thereby helping them to thrive.
Hill-Rom (HRC) FLC Growth Continues, Surgical Arm Stays Dull
by Zacks Equity Research
Within Front Line Care (FLC), Hill-Rom (HRC) registers growth in vital signs monitoring, blood pressure and thermometry as well as the completion of the U.S. stockpile order for noninvasive ventilators.
Boston Scientific (BSX) to Divest BTG's Non-MedTech Arm
by Zacks Equity Research
BTG's core Interventional Medicines business now is expected to exceed Boston Scientific's (BSX) original goal of $175 million in synergies.
Align Technology (ALGN) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Align Technology (ALGN) is optimistic about maintaining a robust product portfolio along with strength in its international business.
4 MedTech Stocks Gaining Ground on COVID-19 Test Kit Success
by Debanjana Dey
Here are a few coronavirus-testing MedTech stocks that investors can scoop up to reap profits amid the pandemic-battered stock market situation.
Baxter (BAX) Announces Site Expansion to Improve Patient Care
by Zacks Equity Research
Baxter's (BAX) latest site expansion is aimed at better serving its client and patient pool along with employment creation.
Here's Why You Should Invest in Syneos Health (SYNH) Now
by Zacks Equity Research
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery in the Clinical Solutions segment and strategic partnerships.